Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
TLSI Stock Chart & Stats
$6.11
-$0.05(-0.97%)
At close: 4:00 PM EST
$6.11
-$0.05(-0.97%)
Day’s Range― - ―
52-Week Range$3.42 - $7.95
Previous CloseN/A
Volume4.84K
Average Volume (3M)193.21K
Market Cap
$305.28M
Enterprise Value$211.65M
Total Cash (Recent Filing)$22.69M
Total Debt (Recent Filing)$34.12M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Apr 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding49,964,310
10 Day Avg. Volume71,749
30 Day Avg. Volume193,214
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-5.13
Price to Sales (P/S)4.51
P/FCF Ratio-3.22
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue5.26
Enterprise Value/Gross Profit6.26
Enterprise Value/Ebitda-6.28
Forecast
1Y Price Target
$11.80Price Target Upside93.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$65.34M
Bulls Say, Bears Say
Bulls Say
Market OpportunityAnalyst highlights that TriNav's potential use in uterine fibroids, multinodular goiter, and genicular artery embolization expands the company's addressable market to about $2.5 billion, creating multiple growth avenues.
Product Portfolio ExpansionThe rollout of new TriNav iterations and the TriNav FLX broadens the product portfolio, supporting entry into additional therapeutic indications and deeper penetration within interventional radiology accounts.
Reimbursement AccessA dedicated HCPCS mapping code improves reimbursement pathways, making it easier for providers to bill for TriNav procedures and increasing procedural access across centers.
Bears Say
Adoption BarriersLow patient awareness of uterine fibroid embolization and poorly established referral pathways between gynecology and interventional radiology may slow adoption of TriNav in that indication.
Profitability PressureGross margin has been adversely affected by inefficiencies tied to new product introductions, which could constrain profitability as the business scales.
Valuation AssumptionsAnalysts removed potential royalty assumptions for nelitolimod from valuation models, reducing modeled revenue expectations and weighing on the stock's valuation.
TriSalus Life Sciences News
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $3.42 and its highest was $7.95 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
TriSalus Life Sciences’s market cap is $305.28M.
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Apr 06, 2026 which is in 88 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Nov 13, 2025. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.149 by -$0.811.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -0.14.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 49,964,310 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.149. Following the earnings report the stock price went up 3.872%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Currently, no hedge funds are holding shares in TLSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TriSalus Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.80 (93.13% Upside)
$11.80 (93.13% Upside)
Blogger Sentiment
Neutral
TLSI Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 45.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 23.4%
Last 30 Days ▲ 23.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
32.70%
Trailing 12-Months
Company Description
TriSalus Life Sciences
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
TLSI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth, expansion of the TriNav platform, and increased commercial investment, demonstrating strong market momentum. However, challenges such as declining gross margins, increased R&D expenses, and higher operating losses indicate areas of concern. Despite these challenges, the company's strategic investments and market opportunities position it for continued growth.View all TLSI earnings summariesTLSI Stock 12 Month Forecast
Average Price Target
$11.80
▲(93.13% Upside)
Technical Analysis
Ownership Overview
31.00% Insiders
3.08% Mutual Funds
11.73% Other Institutional Investors
51.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---